Magrey M, Wolin DL, Mordin MM, McLeod LD, Davenport EK, Hur P. US patient satisfaction with Secukinumab treatment among patients with both psoriatic arthritis and psoriasis: data from a web-based survey. Poster presented at the 2018 Winter Clinical Dermatology Conference; January 2018. Hawaii. [abstract] Skin: the journal of cutaneous medicine. 2018 Feb 23; 2(2018). doi: 10.25251/skin.2.supp.25
Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652
Glaser DA, Hebert AA, Fehnel S, DiBenedetti D, Nelson L, Drew J, Pariser DM. Confirmatory psychometric evaluation of the axillary sweating daily diary: a vaildated patient-reported outcome measure to assess axillary hyperhidrosis sweating severity. Poster presented at the 36th Fall Clinical Dermatology Conference; October 2017. Las Vegas, NV. [abstract] Skin: the journal of cutaneous medicine. 2017; 1(Suppl 93):s94. doi: 10.25251/skin.1.supp.93.
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.